Serum levels of estradiol and follicle stimulating hormone,and vasomotor symptoms in Thai women receivingGnRH analogue before laparoscopic enucleationof endometriotic cysts
This study found that leuprolide acetate suppressed estradiol and FSH levels in Thai women with endometriotic cysts, leading to amenorrhea and increased vasomotor symptoms in some.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This study investigated serum estradiol (E2) and follicle-stimulating hormone (FSH) levels and vasomotor symptoms in 60 Thai women (ages 15–44) with endometriotic cysts treated with leuprolide acetate 3.75 mg intramuscularly every month for 3 months prior to laparoscopic enucleation. Serum E2 and FSH were measured at baseline and at 1, 2, and 3 months, and vasomotor symptoms were assessed using the Thai version of the Greene climacteric score; the main limitation noted from the abstract is that follow-up was limited to the 3-month treatment window. E2 levels decreased significantly by 1 month, and FSH decreased significantly at 1–3 months; by 3 months, most women had amenorrhea (93.3%) with relatively low use of sedative medication (8.3%) despite higher mean vasomotor symptom scores at 2 and 3 months. This paper is centrally about endometriosis — it studies GnRH analogue–induced suppression of ovarian hormones and resulting vasomotor symptoms in women with endometriotic cysts undergoing preoperative treatment.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
2,246 characters
· extracted from
oa-doi-fallback
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (10)
- Changing concepts of medical treatment of endometriosis via openalex
- Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis via openalex
- Efficacy of Gonadotropin-Releasing Hormone Agonist and an Extended-Interval Dosing Regimen in the Treatment of Patients with Adenomyosis and Endometriosis via openalex
- GnRH agonists and add‐back therapy: is there a perfect combination? via openalex
- Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up via openalex
- Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up*1 via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. via openalex
- The Effects of Combining Norethindrone with a Gonadotropin-Releasing Hormone Agonist in the Treatment of Symptomatic Endometriosis via openalex
- W116864337 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00